Latest News

Phase 2 BEACON findings published in JAMA Dermatology demonstrate rapid improvements in disease activity and skin-related quality of life with oral brepocitinib.

Phase 2 AMETHYST findings show continued improvements in skin redness and clinician- and patient-reported outcomes with litifilimab.

Phase 2/3 data show sustained hair growth and favorable safety outcomes with oral VDPHL01 in men with androgenetic alopecia.

BE BOLD Week 24 data show sustained numerical advantages in joint responses with bimekizumab versus risankizumab in active psoriatic arthritis.

A single subcutaneous dose led to a 4-point or greater itch reduction in 82% of patients with chronic pruritus at week 12 vs 22% with placebo, Attovia reported.

At a Dermatology Times Case-Based Roundtable event, Carolyn Goh, MD, led clinicians through a discussion of severity scoring, patient-reported outcomes, CYP2C9 testing, and long-term monitoring across 3 alopecia areata cases.

The AADA warns that dermatologists could face a 6% Medicare payment reduction in 2027 despite CMS revisions to modifier 25 policies.

Pediatric dermatologists outline how to evaluate suspected topical steroid withdrawal, exclude mimics, and preserve family trust in eczema care.

Diego Ruiz Dasilva, MD, and Lindsey Finklea, MD, discuss the burden of chronic inducible urticaria and phase 3 remIND findings for remibrutinib.

Gaurav Singh, MD, MPH, explains how pharmacokinetics, trial design, and real-world tolerability set sonidegib apart from vismodegib in locally advanced basal cell carcinoma and when to start systemic therapy earlier.

Explore the top headlines of the month, including insights on the latest clinical trials, therapeutic updates, and more.

Dermatology Times is looking back on the top stories in dermatology from the month of October.

From “Botox in a bottle” to castor oil and face taping, Dermatology Times reviews the evidence behind 3 viral dermatology trends from October.